

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers subtalar arthroereisis (STA) to be **investigational.***

Background/Overview

Subtalar arthroereisis has been performed for more than 50 years, with a variety of implant designs and compositions. The Maxwell-Brancheau Arthroereisis implant is the most frequently reported, although other devices such as the HyProCure, subtalar arthroereisis peg, and Kalix are also described in the medical literature. The Maxwell-Brancheau Arthroereisis implant is described as reversible and easy to insert, with the additional advantage that it does not require bone cement. In children, insertion of the Maxwell-Brancheau Arthroereisis implant may be offered as a stand-alone procedure, although children and adults often require adjunctive surgical procedures on bone and soft tissue to correct additional deformities.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

A number of implants have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process, a sampling of which are summarized in Table 1. In general, these devices are indicated for insertion into the sinus tarsi of the foot, allowing normal subtalar joint motion while blocking excessive pronation. FDA Product Code: HWC.

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

Table 1. Representative Subtalar Implant Devices Cleared by U.S. Food and Drug Administration^a

Device	Manufacturer	Date Cleared	510(k) No.
Subtalar MBA ^{®†}	Integra LifeSciences	07/96	K960692
OsteoMed Subtalar Implant System	OsteoMed	08/03	K031155
BioPro Subtalar Implant	BioPro	09/04	K041936
HyProCure Subtalar Implant System	Graham Medical Technologies	09/04	K042030
MBA Resorb Implant	Kinetikos Medical	09/05	K051611
Metasurg Subtalar Implant	Metasurg	05/07	K070441
Subtalar Implant	Biomet Sports Medicine	07/07	K071498
Arthrex ProStop Plus Arthroereisis Subtalar Implant	Arthrex	01/08	K071456
Trilliant Surgical Subtalar Implant	Trilliant Surgical	02/11	K103183
Metasurg Subtalar Implant	Metasurg	08/11	K111265
NuGait ^{™†} Subtalar Implant System	Ascension Orthopedic	08/11	K111799
Disco Subtalar Implant	Trilliant Surgical	12/11	K111834
OsteoSpring FootJack Subtalar Implant System	OsteoSpring Medical	12/11	K112658
IFS Subtalar Implant	Internal Fixation Systems	12/11	K113399
The Life Spine Subtalar Implant System	Life Spine	06/16	K160169
Incore Subtalar System	Nextremity Solutions, Inc.	12/21	K213301
Bioplan subtalar implant	BRM Extremities	12/22	K222820

^a FDA 510(k) database search product code HWC

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

Arthroereisis is a surgical procedure that purposely limits movement across a joint. Subtalar arthroereisis or extraosseous talotarsal stabilization is designed to correct excessive talar displacement and calcaneal eversion by reducing pronation across the subtalar joint. Extraosseous talotarsal stabilization is also being evaluated as a treatment of talotarsal joint dislocation. It is performed by placing an implant in the sinus tarsi, which is a canal located between the talus and the calcaneus.

Summary of Evidence

For individuals who have flatfoot who receive subtalar arthroereisis, the evidence includes single-arm observational studies, systematic reviews of observational data, and a small nonrandomized controlled trial comparing subtalar arthroereisis with lateral column calcaneal lengthening. Relevant outcomes are symptoms, functional outcomes, and quality of life. The small nonrandomized comparative trial (N=24 feet) is considered preliminary, and interpretation of the observational evidence is limited by the use of adjunctive procedures in addition to subtalar arthroereisis, creating difficulties in determining the extent to which each modality contributed to the outcomes. Another limitation of the published data is the lack of long-term outcomes, which is of particular importance because the procedure is often performed in growing children. Also, some studies have reported high rates of complications and implant removal. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have talotarsal joint dislocation who receive subtalar arthroereisis, the evidence consists of 1 prospective single-arm study of talotarsal stabilization using HyProCure. Relevant outcomes are symptoms, functional outcomes, and quality of life. Although improvements in pain and function were observed, the current evidence on the use of subtalar arthroereisis for treatment of talotarsal joint dislocation is insufficient to draw conclusions about treatment efficacy with certitude. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Clinical Input from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2012 Input

In response to requests, input was received through 2 physician specialty societies and 2 academic medical centers while this policy was under review in 2012. Input was mixed, with most reviewers considering this procedure to be investigational.

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

2009 Input

In response to requests, input was received through 1 physician specialty society (3 reviews) and 5 academic medical centers while this policy was under review in 2009. Input was mixed regarding the medical necessity of arthroereisis.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Foot and Ankle Surgeons

Piraino et al (2020) published the following Clinical Consensus Statement on the appropriate clinical management of adult-acquired flatfoot deformity: "Subtalar arthroereisis should not be considered as a single corrective procedure for stage IIB AAFD [adult flatfoot]."

National Institute for Health and Care Excellence

Guidance from the National Institute for Health and Care Excellence (2009) concluded that current evidence on the safety and efficacy of sinus tarsi implant insertion for mobile flatfoot was inadequate in quality and quantity.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

A search of [ClinicalTrials.gov](https://clinicaltrials.gov) in March 2026 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Galán-Oller M, Del Baño Barragán L, Figueroa MJ, et al. Outcomes of the "Calcaneo-stop" procedure for treating symptomatic flexible flatfoot in children: A systematic review and meta-analysis of 2394 feet. *Foot Ankle Surg.* Oct 2024; 30(7): 535-545. PMID 38714453
2. Metcalfe SA, Bowling FL, Reeves ND. Subtalar joint arthroereisis in the management of pediatric flexible flatfoot: a critical review of the literature. *Foot Ankle Int.* Dec 2011; 32(12): 1127-39. PMID 22381197
3. Chong DY, Macwilliams BA, Hennessey TA, et al. Prospective comparison of subtalar arthroereisis with lateral column lengthening for painful flatfeet. *J Pediatr Orthop B.* Jul 2015; 24(4): 345-53. PMID 25856275

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

4. Khury F, Danto E, Taurman R, et al. Clinical and radiographic efficacy of subtalar screw arthroereisis in the treatment of pediatric flexible flatfoot. *Eur J Orthop Surg Traumatol.* Feb 19 2026; 36(1): 106. PMID 41711996
5. Silva S, Tavernini T, Bruschi A, et al. Calcaneo-stop for paediatric idiopathic flexible flatfoot: High functional results and return to sport in 644 feet at mid-term follow-up. *J Exp Orthop.* Jan 2025; 12(1): e70182. PMID 39980608
6. Graham ME, Jawrani NT, Chikka A. Extraosseous talotarsal stabilization using HyProCure® in adults: a 5-year retrospective follow-up. *J Foot Ankle Surg.* 2012; 51(1): 23-9. PMID 22196455
7. Moraca G, Martinelli N, Bianchi A, et al. Subtalar arthroereisis with metallic implant is a safe and effective treatment for pediatric patients with symptomatic flexible flatfeet. A 10-year clinical and radiographic follow-up. *Foot Ankle Surg.* Jan 2025; 31(1): 31-37. PMID 38972783
8. Vedantam R, Capelli AM, Schoenecker PL. Subtalar arthroereisis for the correction of planovalgus foot in children with neuromuscular disorders. *J Pediatr Orthop.* 1998; 18(3): 294-8. PMID 9600551
9. Nelson SC, Haycock DM, Little ER. Flexible flatfoot treatment with arthroereisis: radiographic improvement and child health survey analysis. *J Foot Ankle Surg.* 2004; 43(3): 144-55. PMID 15181430
10. Needleman RL. A surgical approach for flexible flatfeet in adults including a subtalar arthroereisis with the MBA sinus tarsi implant. *Foot Ankle Int.* Jan 2006; 27(1): 9-18. PMID 16442023
11. Cicchinelli LD, Pascual Huerta J, García Carmona FJ, et al. Analysis of gastrocnemius recession and medial column procedures as adjuncts in arthroereisis for the correction of pediatric pes planovalgus: a radiographic retrospective study. *J Foot Ankle Surg.* 2008; 47(5): 385-91. PMID 18725117
12. Lucaccini C, Zambianchi N, Zanotti G. Distal osteotomy of the first metatarsal bone in association with sub-talar arthroerisis, for hallux valgus correction in abnormal pronation syndrome. *Chir Organi Mov.* Dec 2008; 92(3): 145-8. PMID 19082522
13. Scharer BM, Black BE, Sockrider N. Treatment of painful pediatric flatfoot with Maxwell-Brancheau subtalar arthroereisis implant a retrospective radiographic review. *Foot Ankle Spec.* Apr 2010; 3(2): 67-72. PMID 20400415
14. Brancheau SP, Walker KM, Northcutt DR. An analysis of outcomes after use of the Maxwell-Brancheau Arthroereisis implant. *J Foot Ankle Surg.* 2012; 51(1): 3-8. PMID 22196453
15. Bresnahan PJ, Chariton JT, Vedpathak A. Extraosseous talotarsal stabilization using HyProCure®: preliminary clinical outcomes of a prospective case series. *J Foot Ankle Surg.* 2013; 52(2): 195-202. PMID 23313499
16. Scher DM, Bansal M, Handler-Mataras S, et al. Extensive implant reaction in failed subtalar joint arthroereisis: report of two cases. *HSS J.* Sep 2007; 3(2): 177-81. PMID 18751791
17. Saxena A, Nguyen A. Preliminary radiographic findings and sizing implications on patients undergoing bioabsorbable subtalar arthroereisis. *J Foot Ankle Surg.* 2007; 46(3): 175-80. PMID 17466243
18. Cook EA, Cook JJ, Basile P. Identifying risk factors in subtalar arthroereisis explantation: a propensity-matched analysis. *J Foot Ankle Surg.* 2011; 50(4): 395-401. PMID 21708340

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

19. Piraino JA, Theodoulou MH, Ortiz J, et al. American College of Foot and Ankle Surgeons Clinical Consensus Statement: Appropriate Clinical Management of Adult-Acquired Flatfoot Deformity. J Foot Ankle Surg. 2020; 59(2): 347-355. PMID 32131002
20. National Institute for Health and Care Excellence (NICE). Sinus Tarsi Implant Insertion for Mobile Flatfoot [HTG196]. 2009; <https://www.nice.org.uk/guidance/htg196>.

Policy History

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

12/07/2017	Medical Policy Committee review
12/20/2017	Medical Policy Implementation Committee approval. New policy.
12/06/2018	Medical Policy Committee review
12/19/2018	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2019	Coding update
12/05/2019	Medical Policy Committee review
12/11/2019	Medical Policy Implementation Committee approval. No change to coverage.
	Coding update
07/02/2020	Medical Policy Committee review
07/08/2020	Medical Policy Implementation Committee approval. No change to coverage.
07/01/2021	Medical Policy Committee review
07/14/2021	Medical Policy Implementation Committee approval. No change to coverage.
07/07/2022	Medical Policy Committee review
07/13/2022	Medical Policy Implementation Committee approval. No change to coverage.
07/06/2023	Medical Policy Committee review
07/12/2023	Medical Policy Implementation Committee approval. No change to coverage.
07/02/2024	Medical Policy Committee review
07/10/2024	Medical Policy Implementation Committee approval. No change to coverage.
07/03/2025	Medical Policy Committee review
07/09/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
07/02/2026	Medical Policy Committee review
07/08/2026	Medical Policy Implementation Committee review.
07/16/2026	Medical Quality Management Committee approval. Coverage eligibility unchanged

Next Scheduled Review Date: 07/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0335T, 0510T, 0511T, 28899
HCPCS	S2117
ICD-10 Diagnosis	M21.40-M21.42, Q66.50-Q66.52

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

Subtalar Arthroereisis

Policy # 00592

Original Effective Date: 12/20/2017

Current Effective Date: 08/01/2026

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.